Regenexx

Regenexx, launched in 2005 by interventional orthopedics specialists Dr. Chris Centeno and Dr. John Schultz in Colorado, revolutionized regenerative medicine by becoming the first to use bone marrow concentrate (BMC) containing mesenchymal stem cells (MSCs) for orthopedic conditions, offering alternatives to surgery for joint pain, arthritis, and injuries. The network emphasizes patented, image-guided protocols for precise delivery of patients’ own cells, prioritizing safety, research, and outcomes tracking through the world’s largest registry for MSC re-implantation in orthopedics.

Regenexx’s mission is to advance interventional orthobiologics—using minimally manipulated autologous cells to promote natural healing—while maintaining FDA compliance for same-day procedures and contributing to evidence-based practices. With a doctorate-level research team and on-site lab, it funds university-style R&D, publishing ~44% of global BMC orthopedic research.

Procedures & Achievements:

Core offerings include Regenexx-SD (same-day BMC with MSCs for joints/spine), Super Concentrated Platelets (SCP, advanced PRP), and Platelet Lysate for nerve/tissue support—all performed under fluoroscopy or ultrasound for accuracy. Procedures target knees, hips, shoulders, back, and more, with a patient registry tracking outcomes (e.g., reduced pain/improved function in thousands). Milestones: World’s largest stem cell safety paper (2016); over 90,000 procedures; 2025 corporate programs serving 2,000+ employers for cost-effective MSK care; IRB-approved early studies (2007).

Following a high-profile FDA lawsuit (2008–2014) over cultured cells (Regenexx-C, deemed a drug), U.S. operations shifted to minimally manipulated same-day protocols; cultured options continue in the Cayman Islands. As of 2025, affiliates affirm FDA compliance, with no embryonic/amniotic/exosome use. Patient reviews often praise pain relief, though success varies (e.g., better for mild-moderate issues; higher failure in severe arthritis).

Supported by network fees and self-funded research, Regenexx trains providers via the Interventional Orthopedics Foundation.